Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD

Human Psychopharmacology

Volumn 24, Issue 2, 2009, Pages 95-102

  Kim, Yeni Kim ^a   Shin, Min Sup ^b   Kim, Jae Won ^b   Yoo, Hee Jung ^b   Cho, Soo Churl ^b   Kim, Boong Nyun ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

ADHD; Continuous performance test; Letter fluency test; Methylphenidate; Trail making test

Indexed keywords

METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; COGNITION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REACTION TIME; SCORING SYSTEM; TREATMENT DURATION; COGNITIVE DEFECT; DELAYED RELEASE FORMULATION; DRUG EFFECT; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADMINISTRATION, ORAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COGNITION DISORDERS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LINEAR MODELS; MALE; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; REACTION TIME;

EID: 63849142517     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1010     Document Type: Article

References (36)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text revised. American Psychiatric Association: Washington DC.
2. Aron AR, Dowson JH, Sahakian BJ, Robbins TW. 2003. Methylphenidate improves response inhibition in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 54: 1465-1468.
3. Barkley RA. 1997. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121: 65-94.
4. Barkley RA, DuPaul GJ, Connor DF. 1999. Stimulants. In Practitioner's Guide to Psychoactive Drugs for Children and Adolescents, 2nd edn, Werry JS, Aman MG (eds). Plenum Press: New York, 213-248.
5. Bedard AC, Martinussen R, Ickowicz A, Tannock R. 2004. Methylphenidate improves visual-spatial memory in children with attention-deficit/ hyper-activity disorder. J Am Acad Child Adolesc Psychiatry 43: 260- 268.
6. Boucugnani LL, Jones RW. 1989. Behaviors analogous to frontal lobe dysfunction in children with attention deficit hyperactivity disorder. Arch Clin Neuropsychol 4: 161-173.
7. Cho SC, Shin YO. 1994. The prevalence of the disruptive behavior disorders. J Kor Acad Child Adolesc Psychiatry 5: 141-149.
8. Coghill DR, Rhodes SM, Matthews K. 2007. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/ hyperactivity disorder. Biol Psychiatry 62: 954-962.
9. DuPaul GJ, Anastopoulos AD, Shelton TL, Guevremont DC, Metevia L. 1992. Multimethod assessment of attention deficit hyperactivity disorder: the diagnostic utility of clinic-based tests. J Clin Child Psychol 21: 394-402.
10. Epstein JN, Erkanli A, Conners CK, et al. 2003. Relations between Continuous Performance Test performance measures and ADHD behaviors. J Abnorm Child Psychol 31: 543-554.
11. Epstein JN, Conners CK, Hervey AS, et al. 2006. Assessing medication effects in the MTA study using neuropsychological outcomes. J Child Psychol Psychiatry 47: 446-456.
12. Felton RH, Wood FB, Brown IS, Campbell SK, Harter MR. 1987. Separate verbal memory and naming deficits in attention deficit disorder and reading disability. Brain Lang 31: 171-184.
13. Gau SS, Chen SJ, Chou WJ, et al. 2008. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 69: 131-140.
14. Hoare P, Remschmidt H, Medori R, et al. 2005. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 14: 305-309.
15. Hurks PP, Hendriksen JG, Vies JS, et al. 2004. Verbal fluency over time as a measure of automatic and controlled processing in children with ADHD. Brain Cogn 55: 535-544.
16. Hwang JW, Kim BN, Cho SC. 2004. Compliance study of MPH-IR in the treatment of ADHD. Korean J Child & Adolesc Psychiatry 15: 178-184.
17. Loge DV, Staton RD, Beatty WW. 1990. Performance of children with ADHD on tests sensitive to frontal lobe dysfunction. J Am Acad Child Adolesc Psychiatry 29: 540-545.
18. Losier BJ, McGrath PJ, Klein RM. 1996. Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: a meta-analytic review. J Child Psychol Psychiatry 37: 971-987.
19. Maassen GH. 2004. The standard error in the Jacobson and Truax Reliable Change Index: the classical approach to the assessment of reliable change. J Int Neuropsychol Soc 10: 888-893.
20. Mehta MA, Goodyer IM, Sahakian BJ. 2004. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 45: 293-305.
21. Modi NB, Wang B, Noveck RJ, Gupta SK. 2000. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol 40: 1141-1149.
22. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. 2001. Once-a-day Concerta. methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107: E105.
23. Pennington BF, Ozonoff S. 1996. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 37: 51-87.
24. Remschmidt H, Hoare P, Ettrich C, et al. 2005. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 14: 297-304.
25. Rhodes SM, Coghill DR, Matthews K. 2006. Acute neuropsychological effects of methylphenidate in stimulant drug-naive boys with ADHD II-broader executive and non-executive domains. J Child Psychol Psychiatry 47: 1184-1194.
26. Riccio CA, Waldrop JJ, Reynolds CR, Lowe P. 2001. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 13: 326-335.
27. Schachar R, Mota VL, Logan GD, Tannock R, Klim P. 2000. Confirmation of an inhibitory control deficit in attention-deficit/hyperactivity disorder. J Abnorm Child Psychol 28: 227-235.
28. Schachter HM, Pham B, King J, Langford S, Moher D. 2001. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165: 1475-1488.
29. Scheres A, Oosterlaan J, Swanson J, et al. 2003. The effect of methylphenidate on three forms of response inhibition in boys with AD/ HD. J Abnorm Child Psychol 31: 105-120.
30. Shallice T, Marzocchi GM, Coser S, et al. 2002. Executive function profile of children with attention deficit hyperactivity disorder. Dev Neuropsychol 21: 43-71.
31. Shin MS, Cho SZ, Chun SY, Hong KE. 2000. A study of the development and stadardization of ADHD diagnostic system. J Kor Acad Child Adolesc Psychiatry 91-99.
32. Solanto MV, Conners CK. 1982. A dose-response and time-action analysis of autonomic and behavioral effects of methylphenidate in attention deficit disorder with hyperactivity. Psychophysiology 19: 658-667.
33. Steele M, Weiss M, Swanson J, et al. 2006. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 13: e50-e62.
34. Swanson J, Gupta S, Lam A, et al. 2003. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 60: 204-211.
35. The MTA Cooperative Group. 1999. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56: 1073-1086.
36. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF. 2005. Validity of the executive function theory of attention-deficit/ hyperactivity disorder: a meta-analytic review. Biol Psychiatry 57: 1336-1346.